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A 28-year-old woman with acquired immunodeficiency syndrome man-
ifest as HIV (CD4 T-cells <10/mM3) and opportunistic infections (prior
cerebral toxoplasmosis and Pneumocystis carinil pneumonia) was admitted
to Hermann Hospital-University of Texas, Houston, with severe dyspnea
and chest pain. An initial chest radiograph revealed bilateral pleural
effusions and massive cardiomegaly. Echocardiography demonstrated a
large pericardial effusion, and a pericardiotomy with window was per-
formed on the first hospital day. Although the patient improved subjec-
tively, she remained febrile, and on the second hospital day pentamidine
was administered on the assumption that the Pneumocystis carinii pneu-
monia had recurred.
Laboratory values on admission were: BUN, 27 mg/dl; creatinine, 1.2
mg/dl; sodium, 138 mEq/liter; potassium, 4.1 mEq/liter; chloride, 107
mEq/liter; and bicarbonate, 23 mEq/liter. Three days after initiation of
pentamidine, the chemistries were as follows: BUN, 72 mg/dl; serum
creatinine, 2.7 mg/dl; sodium, 139 mEq/liter; potassium, 6.8 mEq/liter;
chloride, 111 mEq/liter; bicarbonate, 13 mEq/liter, and serum osmolality,
307 mOsm/kg H20; the Nephrology Service was consulted. The following
urinary chemistries were obtained at that time: sodium, 40 mEq/liter;
potassium, 49 mEq/liter; chloride, 32 mEq/liter; creatinine, 79 mg/dl; and
osmolality, 419 mOsm/kg H20. The calculated transtubular potassium
gradient (TTKG) was 6.0, and the urine net charge (UNC) was +57
mEq/liter. Despite severe hyperkalemia and metabolic acidosis, the elec-
trocardiogram revealed a normal sinus rhythm. Kayexalate was given
rectally and the potassium declined to 5.9 mEq/liter in 12 hours. Penta-
midine administration was discontinued and bicarbonate was adminis-
tered intravenously. The serum potassium declined to 3.5 mEq/liter within
24 hours.
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Discussion
DR. THOMAS D. DUBOSE, JR. (Director, Division of Renal
Diseases and Hypertension, and Professor of Internal Medicine and
Integrative Biology, University of Texas Medical School, Houston,
Texas, USA): This case represents a problem encountered com-
monly by internists and nephrologists: hyperchioremic metabolic
acidosis with hyperkalemia and renal insufficiency in association
with drug nephrotoxicity. Hyperkalemic hyperchloremic meta-
bolic acidosis invariably indicates an abnormality in potassium,
ammonium, and hydrogen ion secretion which, while most evident
in patients with renal insufficiency, is not always the result of a
reduction in renal mass. Indeed, the decrease in whole-kidney
potassium and ammonium excretion is usually out of proportion
to the degree of renal insufficiency (as defined by a decrease in
glomerular filtration rate) and often can be attributed to a
generalized defect in renal tubular function in the cortical and/or
medullary collecting ducts. In this discussion, I will review the
physiology and pathophysiology of potassium and ammonium
excretion, and I will focus on the interrelationship between
potassium and ammonium transport as it pertains to the patho-
physiology of the clinical syndrome of hyperkalemic hyperchior-
emic metabolic acidosis.
Renal potassium secretion
The renal contribution to potassium balance is a homeostati-
cally regulated process accomplished through regulation of potas-
sium secretion across the apical membrane of principal cells in the
cortical collecting duct. The quantity of potassium secretion
depends on the apical membrane potassium conductance and the
electrochemical driving force across the apical membrane. Potas-
sium conductance is defined as the sum of the collective potassium
channels in the apical membrane. Variables that regulate potas-
sium secretion in this nephron segment include factors that affect
the potassium conductance (for example, urine flow and sodium
delivery) and factors that regulate the electrochemical driving
force (for example, potassium balance, transepithelial potential
difference, the pH and bicarbonate concentration of tubule fluid,
systemic acid-base balance, and aldosterone) [1]. The electro-
chemical driving force for potassium secretion is maintained by
the basolateral Na-K-ATPase (that is, the "sodium pump").
Sodium absorption through apical sodium-selective channels
maintains the negative potential difference in the tubular lumen.
The sodium pump generates a negative lumen potential and a
high intracellular potassium concentration, which together aug-
ment potassium secretion. An early effect of aldosterone is
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increased activity of the apical sodium-selective channel; with
time, aldosterone also increases the activity of the basolateral
Na '-K' -ATPase. As expected for a homeostatically regulated
process, potassium secretion varies in parallel with systemic
potassium balance (that is, potassium secretion increases dramat-
ically in acute and chronic hyperkalemia, and decreases in hypo-
kalemia) [1].
Renal potassium excretion is primarily the result of regulation
of tubular potassium secretion. It therefore follows that a clinical
estimate of potassium transfer into the cortical collecting duet
could be helpful in the recognition of hyperkalemia of renal
origin. The transtubular potassium gradient (TFKG) [21 has
emerged as a clinically useful tool for estimating the potassium
concentration "gradient" between the peritubular capillary and
the tubular lumen at the level of the cortical collecting duct
(CCD). A low TTKG in the hyperkalemie patient (<8) implies
that the collecting tubule is not responding appropriately to the
prevailing hyperkalemia and that potassium secretion is impaired.
The formula defining the YI'KG follows:
[K] I [K]TTKG =______
UmIPm
where [KI and [K4} represent potassium concentration in the
urine and plasma, respectively, and Uosm and Osm represent
urine and plasma osmolality respectively. In this expression, the
urine-to-plasma potassium concentration ratio is corrected for
water abstraction in the more distal segments of the collecting
duet. The 171KG computation assumes no significant alteration in
potassium content between the CCD and final urine; that CCD
tubular fluid osmolality is approximately the same as plasma
osmolality; that "osmoles" are not extracted between CCD and
final urine; and that plasma [K] approximates peritubular fluid
[KJ [3]. Under certain clinical conditions, some or none of these
assumptions might be entirely correct [1]. Particularly problematic
is the effect on the YFKG of a dilute urine or of high urine flow
rates (polyuria). In these situations, the 171KG underestimates
potassium secretory capacity in the hyperkalemie patient. With
consideration for these potential pitfalls, the 171KG appears to be
a useful clinical tool for estimating potassium secretory ability, but
it might be no more useful than is the fractional excretion of
potassium (FEK+). Because the hyperkalemia of mineraloeorti-
eoid deficiency should respond to mineralocorticoid replacement,
a patient with hypoaldosteronism would be expected to exhibit an
increase in the TTKG after fludroeortisone administration for
several hours; the 171KG would not be expected to be altered in
a patient with resistance to mineralocortieoid. Thus, an increase in
the TIKO to >8 after mineraloeortieoid administration suggests
aldosterone deficiency; failure of the 171KG to increase suggests
tubular insensitivity to mineraloeortieoid (pseudohypoaldosteron-
ism, voltage defect) [41. The renal causes of hyperkalemia, which
may be evidenced by an inappropriately low 171KG in the
presence of hyperkalemia, are reviewed in Table 1.
Renal ammonium production and transport
Several nephron segments possess ammoniagenie enzymes, but
the majority of ammonium excreted in the urine is derived from
the metabolism of glutamine in proximal tubule cells [5—7].
Ammonium production in the proximal tubule is regulated
through the pivotal enzymes glutaminase and phosphoenolpyru-
vate carboxykinase. In chronic acidosis, the activities of both
enzymes and the abundance of their respective messenger RNAs
increase [8, 9]. At physiologic pH, two ammonium ions and the
divalent anion alpha ketoglutarate (ultimately metabolized to two
bicarbonate ions) are the major products of glutamine metabo-
lism. Figure 1 depicts the nephron segments responsible for
ammonium transport and its regulation. Ammonium is preferen-
tially secreted into the proximal tubular lumen across the apical
membrane [10—13]. Most of the ammonium is secreted in the first
portion of the proximal convoluted tubule [10]. Direct ammonium
secretion occurs via substitution of ammonium for hydrogen ion
on the apical membrane Na/H exchanger [10, 11]. In the S3
segment of the proximal straight tubule, ammonium secretion is
increased by the presence of an acid disequilibrium pH [14].
As fluid leaves the proximal tubule and enters the loop of
Henle, a number of processes lead to ammonium and ammonia
efflux and result in a high medullary interstitial ammonium
concentration. When fluid delivered out of the proximal tubule is
alkalinized in the thin descending limb by water abstraction [15],
a milieu favorable for ammonia efflux by non-ionic diffusion is
created (Fig. 1). Direct ammonium transport across the medullary
thick ascending limb of Henle's loop (mTALH) apical membrane
(by substitution of ammonium for potassium on the Na-2Cl-K
eotransporter) is the major mechanism for absorption and is
responsible for generation of high medullary ammonium concen-
trations [16]. Evidence for this mechanism is the observation that
ammonium absorption is attenuated by luminal application of
furosemide and is competitively inhibited by increasing concen-
trations of potassium [171. In addition, ammonium also might be
absorbed across the apical membrane of the mTALH through
barium-sensitive and -insensitive potassium channels. However,
the physiologic significance of the Na-2Cl-K cotransporter for
ammonium absorption is better understood [18]. The pathway for
ammonium exit across the basolateral membrane is not clearly
defined but likely is achieved through substitution for potassium
on the basolateral potassium conductance [17]. A highly selective
potassium channel that is sensitive to ATP (ROMK-II) has been
cloned and localized to the mTALH [19] and could represent a
channel that is responsible for ammonium uptake across either
membrane of the mTALH.
Ammonia can re-enter the proximal straight tubule from the
interstitium [141, thus leading to countercurrent multiplication,
where the "single effect" involves selective addition of ammonium
by the proximal tubule and active ammonium absorption in the
thick ascending limb of Henle's loop. The countercurrent system
in the loop then multiplies the effect. The net result of this system
is an axial gradient for ammonium. Thus, medullary concentra-
tions of ammonium exceed cortical concentrations severalfold
[20]. As a consequence, the concentrations of ammonium and
ammonia in the medullary interstitium exceed the concentration
Table 1. Causes of hyperkalemia attributed to decreased potassium
excretion
Decrease in distal flow rate
Decrease in sodium delivery
Decrease in secretion of renin or aldosterone
Renal secretory defects
Primary
Secundary
Drugs/toxins
Interstitial diseases
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Fig. 1. Nephron segments responsible for
ammonium excretion. Ammonium excretion is
regulated in response to changes in systemic
acid-base and potassium balance. Segmental
contributions include: proximal convoluted
tubule, proximal straight tubule, thin
descending limb, thick ascending limb, and
4 medullaiy collecting duct. GLN = glutamine.
prevailing in the inner medullary collecting duct (IMCD) lumen.
Thus, a concentration gradient favorable for entry into the
medullary collecting duct is created. Ammoriium concentrations
in the inner medullary interstitium reach the greatest amplifica-
tion over cortical levels during chronic metabolic acidosis [21].
The high concentration of ammonium in the inner medulla can be
obliterated by medullary washout and selective medullary destruc-
tion (for example, in chronic tubulointerstitial diseases).
Ammonium is secreted from the medullary interstitium into the
medullary collecting ducts by a combination of ammonia diffusion
and active hydrogen ion secretion (H-ATPase and HKt
ATPase). These processes result in high concentrations of ammo-
nium in final urine. In addition, ammonium entry into the
terminal IMCD (tIMCD) cell on the basolateral membrane is also
accomplished by competition of ammonium for potassium on the
sodium pump (Na-K-ATPase) [22]. A role for the Na-K-
ATPase in ammonium transport in other collecting duct segments
has not been established, however. The final step in ammonium
secretion into the lumen of the tIMCD has not been elucidated
unambiguously. It is generally assumed that ammonia diffuses
across the apical membrane of the tIMCD in parallel with
hydrogen ion secretion. An additional possibility, as displayed in
Figure 2, is through an ROMK channel in the apical membrane in
competition with potassium. Pathways for ammonia/ammonium
transport in the medulla are summarized in Figure 2.
Metabolic acidosis increases ammonium production through
stimulation of glutaminase and phosphoenolpyruvate carboxyki-
nase primarily in the proximal tubule [7, 8, 23]. Moreover, in
chronic metabolic acidosis, net ammonium addition to the prox-
imal tubule is increased through augmentation of early proximal
tubule ammonium secretion [71. Therefore, ammonium delivery
out of the late proximal tubule is increased dramatically. In
response to the increase in delivery, ammonium absorption by the
thick ascending limb of Henle's loop is augmented, thus increas-
ing inner medullary interstitial concentrations of ammonia [23].
As a consequence of inner medullary accumulation of ammonia
and the increase in the acid disequilibrium pH in the inner
medullary collecting duct, ammonium addition to the medullary
collecting duct increases [21].
The kidney's response to chronic metabolic acidosis is an
increase in ammonium production and excretion. Therefore, in a
patient with chronic metabolic acidosis of non-renal origin
(whether of high or normal anion gap varieties), an increase in
ammonium excretion ensues. Renal tubular disorders, such as the
renal tubular acidoses (proximal, classical distal, and the general-
ized distal defect with hyperkalemia), are associated with an
inappropriately low ammonium excretion rate when the degree of
systemic acidosis is taken into consideration. In the absence of a
laboratory determination of ammonium concentration in the
urine, the urine anion gap (or the urine net charge) has been
widely accepted as an indirect, clinical means of estimating the
response of urinary ammonium excretion to metabolic acidosis.
This calculation is based on the relative constancy of the unmea-
sured cations, such as magnesium and calcium (excluding ammo-
nium), and unmeasured anions such as phosphate, sulfate, and
organic anions present in the urine. In a person ingesting an
average North American diet, the unmeasured anions exceed the
unmeasured cations by approximately 80 mEq/day; thus on a daily
basis, the sum of urinary Na + K + NH4 = Cl + 80 [24].
Urinary ammonium concentrations usually are estimated from a
spot urine by calculating the urine net charge (UNC) thus:
UNC = [Nat + K] —
2HC03
GLN
NH +
Na (H)
f
H20
NH4
NF13
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Fig. 2. Relationship between ammonium
transport in the medulla,y thick ascending limb of
Henle's loop (mTALH) and the terminal inner
medulla,y collecting duct (tIMCD).
where u indicates urinary concentration. Hyperchioremic meta-
bolic acidosis due to gastrointestinal losses can be differentiated in
the laboratory from a renal defect in ammonium excretion, as
urinary ammonium excretion is typically low in renal tubular
abnormalities and high in patients with extrarenal bicarbonate
loss (for example, diarrhea). As illustrated by the case presenta-
tion, the urine net charge of +57 predicts that little, if any,
ammonium is present in the urine, signifying that the metabolic
acidosis is of renal origin. The calculation of the urine net charge
from a spot urine is derived from consideration of total daily
excretion of unmeasured anions and cations. Thus it is more
accurate when the daily urine volume is approximately one liter.
The higher the urine output, the more unreliable the urine net
charge will be in predicting the urinary [NH4]. In polyuric States,
the calculation of the urinary osmolal gap may be more precise
[24, 25]. The utility of the urine net charge in estimating urinary
ammonium excretion in metabolic acidosis is also affected ad-
versely by ketonuria or the presence of drug anions in the urine.
Calculation of [NH4] in the urine using the urinary osmolal gap
should not be affected adversely by ketoacids, hippurate, or drug
anions in the urine. Since this estimation has not been validated in
a wide variety of clinical circumstances and has a number of
potential pitfalls, the most reliable method for detecting a low
ammonium excretion ratio is by direct measurement of urinary
[NH4] in the clinical laboratory. If the urine sample is diluted
1:100, and if appropriate standards are run, the determination of
the urinary [NH4] will be accurate.
Relationship between potassium and ammonium
production and transport
Hyperkalemia should be regarded as an important determinant
of the renal response to changes in acid-base balance. Potassium
status can affect distal nephron acidification both by direct and
indirect mechanisms. First, the level of potassium in systemic
blood is an important determinant of aldosterone secretion, which
in turn is an important determinant of distal hydrogen ion
secretion. Further, studies in our laboratory over the last five or so
years have established a critical role for potassium in ammonium
synthesis in the proximal tubule and in ammonium excretion
[26—28]. Chronic potassium deficiency increased, while chronic
hyperkalemia suppressed, ammonium production [26]. These
changes in ammonium production also affect medullaiy interstitial
ammonium concentration and buffer availability [27]. Moreover,
the effects of potassium balance on ammonium transport in
proximal tubule and the thick ascending limb of Henle's loop have
been demonstrated [29]. Hyperkalemia had no effect on ammo-
nium transport in the superficial proximal tubule but markedly
impaired ammonium absorption in the thick ascending limb,
reducing inner medullary concentrations of total ammonia and
decreasing secretion of ammonia into the IMCD [26, 29]. The
mechanism for impaired absorption of ammonium in the TALH is
competition between potassium and ammonium for the potassium
secretory site on the Na-2Cl-K transporter, and perhaps for the
apical (and basolateral) potassium channel as well [17, 18].
Hyperkalemia also might decrease entry of ammonium into the
medullary collecting duct through competition of ammonium and
potassium for the potassium-secretory site on the basolateral
membrane sodium pump [18].
In summary, hyperkalemia can dramatically affect amnionium
production and excretion. Chronic hyperkalemia decreases am-
monium production in the proximal tubule and whole kidney,
inhibits absorption of ammonium in the mTALH, reduces mcd-
ullary interstitial concentrations of ammonium and ammonia, and
decreases entry of ammonium and ammonia into the medullary
collecting duct. The potential for development of a hyperchior-
ernie metabolic acidosis is greatly augmented when renal insuffi-
ciency coexists with the hyperkalemia, or in the presence of
aldosterone deficiency or resistance. Such a cascade of events
helps to explain, in part, the hyperchloremic metabolic acidosis
and reduction in net acid excretion characteristic of several
experimental models of hyperkalemic-hyperchloremic metabolic
acidosis, including obstructive nephropathy, selective aldosterone
mTALH tIMCD
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Table 2. Animal models of hyperkalemic hyperchloremic metabolic
acidosis
Chronic amiloride administration: voltage defect
Post-obstructed kidney: pump defect
Selective aldosterone deficiency:
Pump/voltage/NH4 deficiency
Chronic dietary hyperkalemia: NH3/NH4 deficiency
deficiency, chronic amiloride administration, and chronic dietary
hyperkalemia in the rat [26, 30, 31].
Acidification defects associated with distal nephron dysfunction
Experimental models. Experimental models of hyperkalemic hy-
perchloremic metabolic acidosis have done much to elucidate the
mechanisms responsible for this acid-base alteration (Table 2).
Chronic amiloride administration. Studies in our laboratory that
employed microelectrodes to measure disequilibrium pH as an
index of proton secretion, as well as PCO2 in the papillary
collecting duct in rats after administration of amiloride for four
days, revealed that this model of hyperkalemia and metabolic
acidosis is associated with a reduction in proton secretion. Im-
paired potassium secretion in the CCT, the result of such a
"voltage" defect, resulted in hyperkalemia [32, 33].
Unilateral ureteral obstruction (UUO). Another experimental
model of distal renal tubular acidosis associated with hyperkale-
mia is that secondary to unilateral ureteral obstruction. While
findings in the postobstructed kidney are similar in many respects
to the arniloride model discussed previously [30, 33], several lines
of evidence clearly indicate that this disorder results from a
non-voltage-mediated rate defect rather than a "voltage" defect.
In the postobstructed model, the animal is unable to acidify the
urine after an acid challenge, ammonium excretion decreases, the
acid disequilibrium pH is obliterated, and the papillary PCO2 is
markedly reduced [30]; all these sequelae are compatible with a
hydrogen ion pump defect. The decrease in ammonium entry into
the inner medullary collecting duct appears to be the conse-
quence, in part, of the defect in hydrogen ion secretion. The
decrease in bicarbonate transport (JtCO2) observed in vitro in
perfused collecting ducts from rabbits subjected to ureteral ob-
struction appears first in medullary segments [34]. After UUO,
H-ATPase activity is reduced to a greater extent in medullary
than in cortical segments [35]. With immunocytochemical tech-
niques, interruption in the cellular distribution of the 31 kD
subunit of H-ATPase has been reported in rat intercalated cells
[36]. This alteration suggests that the H-ATPase fails to insert
into the apical membrane ("gaps" or "discontinuity") [36]. In
summary, biochemical, in-vitro microperfusion, and in-vivo mi-
cropuncture studies support the view that the proton pump is
impaired in unilateral ureteral obstruction.
Selective aldosterone deficiency. Selective aldosterone deficiency
in the rat impairs hydrogen secretion by the inner medullary
collecting duct [31]. This study also demonstrated impaired
ammonium transfer from the interstitium into the IMCD lumen.
As a result, ammonium excretion was reduced dramatically.
Moreover, as a result of impaired ammonium production, ammo-
nium delivery to the loop of Henle also was reduced. Thus, the
reduction in ammonium transfer to the IMCD could be explained
by a decrease in inner medullary ammonium accumulation. Since
papillary PCO2 was reduced during bicarbonate loading, the rate
of proton secretion also was clearly compromised. Findings in
experimental animals and in patients with adrenal insufficiency
[37—39] provide evidence that mineralocorticoid deficiency can
cause acidosis and impairment of renal acidification, even in the
absence of renal disease or glucocorticoid deficiency. The poten-
tial for systemic metabolic acidosis in such a setting can be
amplified greatly, however, in individuals with renal insufficiency
and a decrease in functioning renal mass. In patients with selective
hypoaldosteronism and chronic renal insufficiency, mineralocorti-
coid administration increases renal acid excretion directly by
increasing renal hydrogen ion secretion, and indirectly by correct-
ing hyperkalernia, the latter allowing ammoniurn production and
excretion to increase [23].
Chronic dietary potassium loading. The importance of hyperka-
lemia in the development of metabolic acidosis due to mineralo-
corticoid deficiency has been verified. In patients with adrenal
insufficiency, correction of hyperkalemia with cation exchange
resins significantly increases net acid excretion (ammonium excre-
tion) and corrects the metabolic acidosis, even in the absence of
aldosterone administration [40, 41]. Using micropuncture studies
in immature rats, we have shown that whole-kidney ammonium
excretion falls significantly in vivo in a model of chronic dietary
potassium loading [261. This decrease in excretion was associated
with a marked reduction in whole-kidney ammonium production,
which occurred despite coexistent chronic metabolic acidosis.
Nevertheless, chronic hyperkalemia did not affect net secretion of
ammonium by the superficial proximal convoluted tubule.
Chronic hyperkalemia impairs accumulation of ammonium in the
inner medulla and significantly compromises the transfer of
ammoniurn into the IMCD [27], at least in part by inhibition of
active ammonium absorption by the medullary TALH. Therefore,
hyperkalemia can lead to metabolic acidosis as a result of a
decrease in ammonium excretion. The tendency for metabolic
acidosis to develop as a consequence of hyperkalemia might
depend on the degree of remaining functional renal mass and the
integrity of the renin-aldosterone system [33, 40].
Clinical disorders. The coexistence of hyperkalemia and hyper-
chlorernic metabolic acidosis suggests generalized distal tubule
dysfunction. Generalized distal nephron dysfunction manifests as
a hyperchioremic hyperkalemic metabolic acidosis, in which uri-
nary ammonium excretion is invariably depressed and renal
glomerular function is often compromised. Although hyperchlor-
ernie metabolic acidosis and hyperkalernia occur with regularity in
advanced renal insufficiency, patients identified and studied sim-
ply because of severe hyperkalemia (>5.5 mEq/liter), for example,
those with diabetic nephropathy and/or tubulointerstitial disease,
have hyperkalemia that is disproportionate to the reduction in
glomerular filtration rate. The transtubular potassium gradient [2]
is usually low in patients with this disorder (<8), indicating that
the collecting tubule is not responding appropriately to the
prevailing hyperkalernia. In such patients, a unique dysfunction of
potassium and acid secretion by the collecting tubule is attributed
to either hypoaldosteronism [42, 431 or to a decrease in effective-
ness of aldosterone [44]. Thus, in patients presenting with this
constellation of findings, an evaluation of renin-aldosterone elab-
oration is indicated. A classification of the clinical disorders
associated with hyperkalemia and acidification defects is proposed
in Table 3.
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Table 3. Pathophysiologic classification of disorders associated with
hyperkalemic hyperchloremic metabolic acidosis
Mineralocorticoid deficiency
Primary
Generalized (Addison's disease)
Isolated (selective aldosterone deficiency)
Secondary
Hyporeninemic
Pharmacologic
Mineralocorticoid resistance
Pseudohypoaldosteronism type 1
Renal tubular dysfunction
Voltage defects
Secondary to drugs that interfere with Na channel function
Pseudohypoaldosteronism type 2
Secondary to tubulointerstitial disease (pseudohypoaldosteronism
type 3)
Hydrogen ion pump defect
Aldosterone deficiency
Obstructive uropathy
Mineralocorticoid deficiency. Destruction of the adrenal cortex
by hemorrhage, infection, invasion by tumors, or autoimmune
processes results in Addison's disease, that is, combined glucocor-
ticoid and mineralocorticoid deficiency. Causes of Addison's
disease include tuberculosis, autoimmune adrenal failure, 21-
hydroxylase deficiency, fungal infections, adrenal hemorrhage,
metastasis, lymphoma, AIDS, amyloidosis, and drug toxicity (ke-
toconazole, fiuconazole, phenytoin, rifampin, and barbiturates)
[44, 45]. Addison's disease is manifest by hypoglycemia, anorexia,
weakness, hyperpigmentation, and a failure to respond to stress.
These defects can occur in association with renal salt wasting and
hyponatremia, low plasma aldosterone levels, high levels of
plasma renin activity (PRA), and hyperkalemia and metabolic
acidosis [42—451. The metabolic acidosis of mineralocorticoid
deficiency results from a decrease in hydrogen ion secretion in the
collecting duct secondary to decreased H-ATPase number and
function. The hyperkalemia of mineralocorticoid deficiency, in
turn, decreases ammonium production and excretion.
In contrast to the less common primary adrenal disorder,
patients with hyporeninemic hypoaldosteronism exhibit low
plasma renin activity. Patients are usually older (mean age, 65
years) and commonly exhibit mild to moderate renal insufficiency
(70%) and acidosis (50%) in association with chronic hyperkale-
mia (5.5—6.5 mEq/liter) [43, 46]. The most frequently associated
renal diseases are diabetic nephropathy and tubulointerstitial
disease, systemic lupus erythematosus, and AIDS nephropathy
[44]. For 80% to 85% of such patients, there is a reduction in
plasma renin activity that cannot be stimulated by the usual
physiologic maneuvers. Aldosterone secretion, while low, can be
increased by administration of angiotensin II or ACTH. Since
approximately 30% of patients with hyporeninemic hypoaldoste-
ronism are hypertensive, the finding of a low plasma renin in these
patients suggests a volume-dependent form of hypertension with
physiologic suppression of renin production [461. In general,
patients with more advanced renal insufficiency as a result of
glomerular disease rather than tubulointerstitial disease (for
example, diabetic nephropathy) are more commonly volume
expanded [44, 471. Because either mild salt wasting or salt
retention can occur in this disorder, the precise cause of the
decrease in plasma renin has not been established firmly. As I
mentioned, impaired ammonium excretion is the combined result
of hyperkalemia, impaired ammoniagenesis, a reduction in
nephron mass, reduced proton secretion, and impaired transport
of ammonium by nephron segments in the inner medulla [31, 41.
Isolated hypoaldosteronism, which can occur in critically ill
patients, particularly in the setting of severe sepsis or cardiogenic
shock, is manifest by markedly elevated ACTH and cortisol levels
in association with a decrease in aldosterone elaboration in
response to angiotensin II [48]. This hypoaldosteronism might be
secondary to selective inhibition of aldosterone synthase as a
result of hypoxia, release of cytokines such as TNFs or IL-I, or,
alternatively, high circulating levels of atrial natriuretic peptide
(ANP) [49]. The features of hypoaldosteronism, including hy-
perkalemia and metabolic acidosis, can be potentiated by the
administration of potassium-sparing diuretics, potassium loads in
parenteral nutrition solutions, or heparin, which suppresses aldo-
sterone synthesis in the critically ill patient [50].
Mineralocorticoid resistance. Pseudohypoaldosteronism (PHA)
is characterized by renal resistance to the action of aldosterone.
The clinical features include hyperkalemia (which can be attrib-
uted to impaired potassium secretion), normal or elevated aldo-
sterone levels, and hyperkalemic hyperchioremic metabolic aci-
dosis. By definition, physiologic mineralocorticoid replacement
therapy does not correct the hyperkalemia. Mineralocorticoid
resistance with hyperkalemia can be associated with salt retention
or with salt wasting. Pseudohypoaldosteronism type 1, first de-
scribed in infants with severe salt wasting, hypotension, and
hyperkalemia, is inherited as either an autosomal recessive or
dominant disorder. The collecting tubule is unresponsive to
aldosterone, and some patients demonstrate resistance in other
target organs [51]. This disorder appears to be the result of a
loss-of-function mutation in the c or 3 subunit of the epithelial
sodium channel (ENaC) [521. Adult patients have been reported
with hyperkalemia, hyperchloremic metabolic acidosis, hyperten-
sion, normal renal function, undetectable plasma renin activity,
and low aldosterone levels (pseudohypoaldosteronism type II)
[44]. These patients generally have not exhibited glomerular or
tubulointerstitial disease. The acidosis is mild and can be ac-
counted for solely by the magnitude of hyperkalemia. Further-
more, renal potassium secretion is resistant to mineralocorticoid
administration. Renin and aldosterone levels increase if volume
expansion is corrected by diuretics or salt restriction. In careful
studies, Schambelan et al demonstrated that potassium excretion
responds to sodium sulfate infusion but not to sodium chloride
infusion [53]. They then suggested that this disorder results from
an early distal tubule "chloride shunt." The "shunt" is viewed as
the result of increased chloride reabsorption in the early distal
tubule, which would, by decreasing transepithelial voltage, reduce
the driving force for potassium secretion. Thiazide diuretics
consistently correct the hyperkalemia and metabolic acidosis, as
well as the hypertension and plasma aldosterone and plasma renin
levels; thus it would be reasonable to assume that this disorder
stems from increased activity of the thiazide-sensitive Na -Cl
cotransporter in the connecting tubule [44]. Nevertheless, genetic
linkage studies have failed to establish such a relationship [54].
Pseudohypoaldosteronism can be distinguished from selective
hypoaldosteronism by the presence of hypertension and normal
renal function, the absence of diabetes mellitus and salt wasting,
and the failure to exhibit a kaliuretic response to mineralocorti-
coids. Some authors have described a third type of PHA, which
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Table 4. Acquired renal tubular secretoly defects associated with
hyperkalemic hyperchloremic metabolic acidosisa
Sickle-cell disease
SLE
Renal transplant rejection
Obstructive uropathy
Medullary cystic disease
Drug-induced interstitial nephritis
Analgesic abuse nephropathy
HIV nephropathy
1gM monoctonal gammopathy
—
a Usually associated with decreased renin secretion and impaired re-
sponse of collecting tubule to aldosterone.
occurs in adults with overt salt wasting and tubulointerstitial
disease but without hypertension [55].
Table 4 outlines a number of renal diseases that are commonly
associated with deficient renin elaboration and an attenuated
responsiveness to aldosterone, hyperkalemia, and on occasion
tubulointerstitial involvement [55—57]. Although hyperkalemia is
more likely to be associated with metabolic acidosis and reduced
ammonium excretion when the GFR is below 20—50 mI/mm, in
these disorders significant hyperkalemia can occur with signifi-
cantly less renal functional impairment. Hyperkalemia out of
proportion to the degree of renal insufficiency typically occurs
with the nephropathies associated with sickle cell disease, sys-
temic lupus erythematosus, and obstruction of the collecting
system; with acute and chronic renal allograft rejection; in hypoal-
dosteronism; and occasionally in patients with multiple myeloma
and amyloidosis [53].
An additional disorder that results in hyperkalemic hyperchlo-
remic metabolic acidosis has been dubbed hyperkalemic distal
RTA because of the coexistence of hyperkalemia with the pa-
tient's inability to acidify the urine (U > 5.5) during spontane-
ous acidosis or following an acid load [581. The hyperkalemia
results from impaired renal potassium secretion, and the TTKG
or FEK is invariably lower than that expected for hyperkalemia
[56]. Urinary ammonium excretion is reduced, but aldosterone
levels can be low, normal, or even increased. This variability in
aldosterone levels assists in distinguishing this disorder from
selective hypoaldosteronism. Moreover, in selective hypoaldoste-
ronism, the urinary pH is low, and the defect in urinary acidifica-
tion is attributed to the decrease in ammonium excretion and
hydrogen secretion. Hyperkalemic distal RTA, which is assumed
to be the result of a "voltage defect" in the cortical collecting duct,
appears to occur in a variety of renal diseases [56, 57]. Neverthe-
less, in patients with hyperkalemic RTA and hypoaldosteronism,
no evidence for such a defect could be demonstrated [58]. It was
concluded that acidification was impaired as a result of abnormal
function of the hydrogen ion secretory pump (H-ATPase).
Drugs can impair renin or aldosterone elaboration or cause
mineralocorticoid resistance, which mimics the clinical manifes-
tations of the acidification defect that occurs with the generalized
form of distal RTA with hyperkalemia (Table 5). Cyclo-oxygenase
inhibitors (nonsteroidal anti-inflammatory drugs) can generate
hyperkalemia and metabolic acidosis as a result of inhibition of
renin release [53]. Beta-adrenergic antagonists cause hyperkale-
mia because they alter potassium distribution and interfere with
the renin-aldosterone system. Heparin impairs aldosterone syn-
thesis as a result of direct toxicity to the zona glomerulosa, leading
Table 5. Drug-induced hyperkalemia
Impaired renin-aldosterone elaboration
Cyclo-oxygenase inhibitors
13-adrenergic antagonists
Converting-enzyme inhibitors
Heparin
Inhibitors of renal potassium secretion
Potassium-sparing diuretics
Trimethoprim
Pentamidine
Cyclosporine A
Digitalis overdose
Lithium
Altered potassium distribution
Insulin antagonists (somatostatin, diazoxide)
/3-adrenergic antagonists
a-adrenergic agonists
Hypertonic solutions
Digitalis
Succinylcholine
Arginine hydrochloride, lysine hydrochloride
to inhibition of aldosterone synthase. Angiotensin-converting-
enzyme (ACE) inhibitors interrupt the renin-angiotensin system
and cause hypoaldosteronism with hyperkalemia and acidosis,
particularly in patients with advanced renal insufficiency and those
with a tendency to develop hyporeninemic hypoaldosteronism,
such as those with diabetic nephropathy [56]. The combination of
potassium-sparing diuretics and ACE inhibitors should be
avoided assiduously.
Spironolactone, a competitive inhibitor of aldosterone, fre-
quently causes hyperkalemia and metabolic acidosis when admin-
istered to patients with renal insufficiency [44, 561. Similarly,
amiloride and triamterene can have the same effect [53, 59]. Both
potassium-sparing diuretics block the apical Na-selective chan-
nel in the collecting duct principal cell and thus alter the driving
force for potassium secretion. Amiloride is the prototype for a
growing number of agents that cause hyperkalemia, including
trimethoprim and pentamidine, particularly in patients with
AIDS. Trimethoprim and pentamidine are related structurally to
amiloride and triamterene; all these agents are heterocyclic, weak
bases that exist primarily in the protonated forms in an acidic
urine [60]. Kleyman and Ling demonstrated that the protonated
forms of both trimethoprim and pentamidine inhibit the epithelial
sodium-selective channel in A6 distal nephron cells [60, 61]. This
effect in A6 cells has been verified in rat late distal tubules
perfused in vivo [62]. Hyperkalemia has been observed in 20% to
53% of HIV-infected patients receiving high-dose trimethoprim
(TMP)-sulfamethoxazole (SMX) or TMP-dapsone for the treat-
ment of opportunistic infections, and in as many as 100% of
patients with AIDS-associated infections (Pneumocystis carinii)
receiving pentamidine for more than 6 days [62]. Because both
TMP and pentamidine decrease the electrochemical driving force
for both potassium and hydrogen secretion in the CCT (Fig. 3),
metabolic acidosis frequently accompanies the hyperkalemia,
even in the absence of severe renal failure, adrenal insufficiency,
severe tubulointerstitial disease, or hypoaldosteronism. While it
has been assumed widely that such a "voltage" defect could
explain the decrease in hydrogen ion secretion, it is likely that
hyperkalemia plays a significant role in the development of the
metabolic acidosis through a decrease in ammonium production
598 Nephrology Forum: Hyperkalemic hyperchloremic metabolic acidosis
Fig. 3. Mechanisms of drug-induced voltage defects in the cortical collecting
tubule that inhibit K secretion. Apical Na channel blocked by amiloride,
triamterene, trimethoprim (TMP), and pentamidine, and basolateral Na,
K-ATPase by cyclosporine A (CsA).
and excretion. Ammonium excretion has not been systematically
investigated in patients with hyperkalemia receiving either TMP
or pentamidine thus far, however.
Cyclosporine A (CsA) is associated with hyperkalemia in the
transplant recipient. This drug inhibits basolateral Na,K-
ATPase, thereby decreasing intracellular [K] and the transepi-
thelial potential, which together decrease the driving force for
potassium secretion [631. Sands et al have suggested that the
specific mechanism of CsA inhibition of the sodium pump is
through inhibition by this agent of calcineurin activity [64].
Cyclosporine also could decrease the filtered load of potassium
through hemodynamic mechanisms, such as vasoconstriction,
which decrease GFR and alter the filtration fraction. Additional
mechanisms by which CsA might cause hyperkalemia and meta-
bolic acidosis include mineralocorticoid resistance [65], a distal
hydrogen pump defect [66], and impairment of the apical mem-
brane potassium-selective channel.
Treatment
Documentation of the background upon which hyperkalemic
hyperchloremic metabolic acidosis is expressed provides the basis
for appropriate therapy. Of particular importance is a careful drug
and dietary history. Contributing or precipitating factors include:
low urine flow or decreased distal sodium delivery, a rapid decline
in GFR (especially in acute superimposed on chronic renal
failure), hyperglycemia or hyperosmolality, and unsuspected
sources of exogenous potassium intake. The workup should
include evaluation of the 3TFKG and its response to furosemide
and fludrocortisone, an estimate of renal ammonium excretion
(urine net charge, urine osmolar gap, and urine pH), and evalu-
ation of PRA and aldosterone secretion. The last can be obtained
under stimulated conditions utilizing dietary salt restriction and
furosemide-induced volume depletion.
The decision to treat often is based on the severity of the
hyperkalemia. A reduction in serum potassium often improves the
metabolic acidosis by increasing ammonium excretion as potas-
sium levels return to the normal range [44]. Patients with com-
bined glucocorticoid and mineralocorticoid deficiency should
receive both adrenal steroids in replacement dosages. Patients
with hyporeninemic hypoaldosteronism usually respond to a
cation-exchange resin (sodium polystyrene sulfonate), alkali ther-
apy, or treatment with a ioop diuretic. Volume depletion should
be avoided unless the patient is volume overexpanded or hyper-
tensive. Supraphysiologic doses of mineralocorticoids are some-
times necessary but should be administered cautiously in combi-
nation with a loop diuretic to avoid volume overexpansion or
aggravation of hypertension [56]. Infants with pseudohypoaldo-
steronism type I should receive a salt supplement in amounts
sufficient to correct the syndrome and allow normal growth;
patients with pseudohypoaldosteronism type IT should receive
thiazide diuretics along with dietary salt restriction [441. Although
it seems prudent to discontinue drugs identified as likely causes of
the hyperkalemia, this is not always feasible in the patient with a
life-threatening disorder, for example, during TMP-SMX or pen-
tamidine therapy in the atovaquone (Mepron)-sensitive AIDS
patient with Pneumocystis carinii pneumonia. The mechanism by
which TMP and pentamidine cause hyperkalemia (voltage defect)
might lead one to reason that the delivery to the cortical collecting
duct of a poorly reabsorbed anion might improve the electro-
chemical driving force, favoring potassium and hydrogen secre-
tion. The combined use of acetazolamide with sufficient sodium
bicarbonate to deliver significant amounts of bicarbonate to the
cortical collecting tubule, thereby increasing the negative trans-
epithelial voltage, theoretically could increase potassium and
hydrogen ion secretion [63]. Obviously, with such an approach,
aggravation of metabolic acidosis by excessive acetazolamide or
insufficient sodium bicarbonate administration must be avoided.
This approach, however, has not yet been corroborated by clinical
trials.
In summary, hyperkalemia plays a pivotal role in the kidney's
response to metabolic acidosis. Hyperkalemia impairs ammonium
production and transport in the proximal tubule, as well as
ammonium transport in the thick ascending limb of Henle's loop
and the medullary collecting duct. The competitive inhibition by
hyperkalemia of thick limb absorption in turn impairs the coun-
tercurrent system in the renal medulla, which reduces ammonium
entry into the inner medullary collecting duct, thus decreasing net
acid excretion. This cascade of events is most commonly seen in
hyperkalemic hyperchloremic metabolic acidosis as a result of
impaired renin release or angiotensin formation, aldosterone
secretion or action, or collecting tubule sodium transport. These
disorders, often associated with a generalized defect in potassium
and hydrogen ion secretion in the collecting duct, are sometimes
designated collectively as type-TV distal renal tubular acidosis.
Several drugs related structurally to amiloride, such as tn-
methoprim and pentamidine, impair sodium absorption by inter-
fering with the epithelial sodium channel in the apical membrane
of the collecting duct. As a result of impaired sodium absorption,
a "voltage" lesion occurs that compromises potassium secretion
Amiloride
Triamterene
TMP
Pentamidine
Na
K
CCT ( principal cell)
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secondarily. Clinical assessment of potassium secretion is pro-
vided by calculation of the fractional excretion of potassium or the
transtubular potassium gradient. In addition, the ammonium
concentration in the urine can be estimated in the acidotic patient
by calculation of the urine net charge. Treatment should be
directed toward correction of the hyperkalemia, restoration of
euvolemia, adequate alkali therapy, loop diuretics, and dietary
potassium restriction. In severe hypoaldosteronism, the effect of
loop diuretics can be augmented significantly by administration of
small doses of mineralocorticoid. Fludrocortisone should be used
cautiously, however, and avoided in the presence of hypertension
or congestive heart failure.
Questions and answers
DR. NIc0LA0s E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): As you know,
Ang II itself has now been regarded as an important modulator of
proximal acidification processes as well as of renal ammonia
production and transport [67, 68]. Could you please comment on
the potential direct effects of Ang II in the acidification defect of
hyporeninemic hypoaldosteronism?
DR. DuBosu: Clearly, more investigation is needed to elucidate
the role of angiotensin II in the development of metabolic acidosis
in association with hyporeninemia. As you mentioned, it is well
established that Ang II increases bicarbonate absorption in the S
segment by inhibiting adenylyl cyclase. The principal pathway for
selective addition of ammonium into the proximal tubule is
through substitution of ammonium on the apical sodium/proton
exchanger. Nagami has shown that luminal Ang II increases
selective ammonium addition in the proximal tubule in parallel
with stimulation of luminal acidification [68]. In hyporeninemic
hypoaldosteronism per se, one would anticipate a marked reduc-
tion in ammonium secretion in the proximal tubule. In our model
of selective aldosterone deficiency, we did not specifically examine
proximal ammonium secretion. Angiotensin II inhibitors may be
associated with hyperkalemia and metabolic acidosis, of course,
but this complication appears to occur when there has been
tubulointerstitial disease and/or a significant reduction in renal
mass. Our models predict that in this setting, both potassium and
hydrogen ion secretion are impaired in the collecting duct.
Hyperkalemia further compromises net acid excretion by inhibit-
ing both ammonium production and excretion. The effect of Ang
II on ammonium transport in the inner medulla has not been
examined directly, however.
DR. MADIAS: In reflecting on the acidification defect of hy-
poreninemic hypoaldosteronism, one would expect features of a
voltage-dependent acidification defect. Yet patients with hy-
poreninemic hypoaldosteronism don't exhibit sodium wasting
unless placed on severe sodium restriction, and they maintain the
ability to acidify the urine normally. Do you think that the basic
acidification defects underlying hyporeninemic hypoaldosteron-
ism and hyperkalemic distal RTA are essentially the same but
quantitatively more expressed in the latter syndrome?
DR. DUBOSE: I agree that these disorders appear to represent a
continuum of the same defect. In the model of selective aldoste-
rone deficiency, I believe that the bulk of the evidence is more
compatible with a "pump" defect rather than with a "voltage"
defect. Support for this point of view is provided by studies in both
the turtle bladder and the isolated perfused collecting tubule. It is
clear that aldosterone directly and specifically impairs proton
pump function in the outer medullary collecting duct, where
"voltage" would not be a factor. Aldosterone deficiency therefore
appears to compromise the function or reduce the number of
proton pumps in the membrane.
DR. JOHN T. HARRINGTON (Dean ad interim, Tufts University
School of Medicine, Boston, Massachusetts): I have two questions.
First, in regard to the TTKG, could you tell us the validity,
sensitivity, specificity, etc., supporting the concept that a ratio of
less than 8 signifies renal hyperkalemia, or is that figure simply an
arbitrary definition? Second, why do only 50% or so of patients
with hyporeninemic hypoaldosteronism actually have metabolic
acidosis? Shouldn't it be 100%?
DR. DuBosE: The TTKG represents a simple computation that
helps place the pathophysiology of hyperkalemia into perspective.
It should be viewed as nothing more than a diagnostic aid, not a
definitive test. The validity of the TT'KG has not been tested
rigorously, but there are numerous assumptions and potential
pitfalls.
To answer your second question, I don't know why 100% of
patients with isolated hypoaldosteronism don't develop metabolic
acidosis. There are a number of mechanisms by which ammonium
excretion can be increased to compensate for simple hyperkale-
mia. The simultaneous occurrence of metabolic acidosis and
hyperkalemia seems to require either aldosterone deficiency or
resistance, a decrease in functional renal mass, or impaired
tubular transport.
DR. MADIAs: Are there good observations on the level of
plasma aldosterone in patients with hyporeninemic hypoaldoste-
ronism following correction of the hyperkalemia?
DR. DUBOSE: A few studies have examined this question
indirectly. Szylman and colleagues first showed that correction of
hyperkalemia by Kayexalate was associated with repair of meta-
bolic acidosis [69]. This repair of acidosis occurred in tandem with
an increase in urinary ammonium excretion. These changes took
place irrespective and independent of aldosterone; pharmacologic
doses of fludrocortisone did not correct the hyperkalemia or the
acidification defect.
DR. JAMES STROM (Division of Nephrology, St. Elizabeth's Hos-
pital, Brighton, Massachusetts): What distinguishes pseudohypoal-
dosteronism type II from hyporeninemic hypoaldosteronism? If I
understood your categorization correctly, the groups have similar
hormone levels and may require similar supraphysiologic replace-
ment of mineralocorticoid.
DR. DUBOSE: Patients with hyporeninemic hypoaldosteronism
often have significant renal insufficiency. Pseudohypoaldosteron-
ism type II can occur with a normal GFR. These latter patients are
resistant to large doses of mineralocorticoid and are volume-
expanded. The primary abnormality in PHA type II has been
proposed to be of tubular origin, the "chloride shunt," or in-
creased CL transport, which causes the volume expansion, hyper-
tension, and hyperkalemic metabolic acidosis.
DR. AJAY SINGH (Division of Nephrology, New England Medical
Center): Among patients with hyporeninemic hypoaldosteronism,
there appear to be a significant number in whom aldosterone
secretion cannot be independently stimulated by ACTH or angio-
tensin II [70, 71]. This would suggest that other factors play a role
in suppressing aldosterone. Indeed, one study suggests that ANP
is this factor [72]. Can you comment on this phenomenon and
update us on any recent studies that might have examined this
issue?
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DR. DUBOSE: The consensus has been that when renin is
depressed as a result of volume expansion, aldosterone produc-
tion will not increase in response to hyperkalemia. Insulin defi-
ciency also might play a role. As you point out, a deficient
response of ANP to volume expansion can accompany PHA type
II or Gordon's syndrome, but there is no direct information to
support such an association.
DR. GEETHA NARAYAN (Division of Nephrology, St. Elizabeth s
Hospital): It has been postulated that severe volume depletion can
help perpetuate even simple metabolic acidosis, such as acidosis
resulting from diarrhea. It also has been postulated that this may
result from a reversible distal acidification defect, resulting in
decreased ammonium excretion, Can you comment on this, and is
this defect caused by decreased sodium availability in the distal
nephron, coupled with more efficient chloride absorption, produc-
ing a voltage-type defect?
DR. DUBOSE: Yes, in the scenario you describe, decreased
delivery of sodium ultimately could lead to impaired potassium
and hydrogen ion secretion, which would reduce net acid excre-
tion and cause metabolic acidosis. However, it is not necessary to
superimpose a chloride shunt, because this lesion causes volume
expansion. Extremely low distal sodium delivery or impaired
sodium absorption should be sufficient.
DR. NARix: Is the effect of hyperkalemia on ammonium
production still believed to be mediated, at least in part, through
transcellular cation exchange and intracellular alkalosis?
DR. DUBOSE: Hyperkalemia decreases the uptake of glutamine
and decreases production of ammonium from glutamine precur-
sors. Although the cellular mechanism has not been defined
precisely, it is known that uptake is enhanced by intracellular
acidosis. Whether intracellular alkalosis develops in the proximal
tubule cell during hyperkalemia, or whether it plays a role in the
decrease in ammonium excretion, is not known. In a model of
hyperkalemic metabolic acidosis, David Good and I attributed the
decrease in ammonium excretion to changes in transport beyond
the proximal tubule [26]. This defect was later localized to the
renal medulla [27]. While ammonium production was reduced by
50% and excretion by 40%, there was no change in net ammo-
nium transport in the proximal tubule. Such a disassociation of
proximal production and transport conceivably could occur in
response to intracellular alkalosis. Nevertheless, this effect could
be modulated by the peritubular potassium concentration, which
clearly alters proximal ammonium secretion.
DR. MAIMAS: As you know, some work suggests that ammonia
can exert injurious effects on the kidney by augmenting interstitial
fibrosis via complement activation [73]. In this context, the
decreased ammonia production in tubulointerstitial diseases
might be teleologically adaptive. On the other hand, metabolic
acidosis has its own adversity [74]. Can you reflect a bit on this
issue?
DR. DUBOSE: The interesting study you mentioned [73] sug-
gested that ammonia in the inner medulla could activate the
alternate complement pathway, which could lead to tissue injury
in the form of tubulointerstitial disease. One might speculate that
in tubulointerstitial disease a decrease in ammonium absorption
in the thick limb and a decrease in ammonia accumulation in the
inner medulla might be beneficial in slowing perpetuation of the
injury, as you suggest. This model has not been developed further,
however, and additional work is needed in this area.
DR. HARRJNGTON: I have two questions regarding the concept
of direct ammonium secretion. First, how do you specifically
measure direct ammonium secretion across the distal nephron?
Second, of the total amount of ammonium excreted, how much is
via direct ammonium secretion versus ammonia combining with
hydrogen to be excreted as ammonium?
DR. DUBOSE: The precise delineation of which moiety is
secreted requires consideration of the pK' of ammonium, the pH
of tubule fluid, the total ammonia concentration, and transepithe-
hal potential. To answer your question, each nephron segment's
contribution would have to be defined in each physiologic condi-
tion. This type of study has not been performed. Since the
ammonium excreted is ultimately derived from the ammonium
secreted by the proximal tubule, I would speculate that the
contribution from the "direct" route exceeds the trapping route by
at least twofold.
DR. HARRINGTON: Drawing from your own experience or the
literature, can you quantitate the common causes of hyperkalemia
in hospital patients? That is, how much of the hyperkalemia is due
to disease, and how much is due to administered potassium?
DR. DUBOSE: We have not quantitated such data from our
hospital. The sources of exogenous potassium are significant, but
I think that the incidence of drug nephrotoxicity as a cause of
hyperkalemia is increasing. Patients often receive potassium loads
and drugs that are inappropriate for the degree of renal function.
Examples include nonsteroidal anti-inflammatory drugs, ACE
inhibitors, and potassium-sparing diuretics. At least three groups
of patients are at particular risk: (1) Patients with HIV or AIDS,
with a life-threatening infection, who are receiving pentamidine or
trimethoprim. (2) Patients with diabetes mellitus; very often these
patients receive a multitude of drugs including nonsteroidal
agents and potassium-sparing diuretics, as well as ACE inhibitors,
all of which, especially in combination, can cause severe hyperka-
lemia and metabolic acidosis. (3) Hypoxic patients in the critical
care setting who develop selective hypoaldosteronism with or
without heparin administration.
DR. SINUH: As you stated, one of the drugs implicated as a cause
of drug-induced hypoaldosteronism and hyperkalemia is heparin,
which appears to inhibit 18-hydroxylase in the adrenal gland,
thereby impeding aldosterone biosynthesis [75, 76]. Given that
heparin is used so frequently, I'm surprised that we do not see
more hyperkalemia among our patients in the hospital. Is it a
dose-related effect? Are other factors important?
DR. DUBOSE: Heparin-associated hyperkalemia is limited to
critically ill patients and is not dose-related. As I said, the most
common co-morbidity is hypoxemia.
DR. MADIAs: My experience is that even low-dose heparin can
produce hyperkalemia but not in the presence of normal renal
function. Almost all the patients I have seen have had underlying
renal dysfunction or another independent reason for hyperkale-
mia.
DR. SINGH: Is the development of heparin-induced hyperkale-
mia observed in patients treated with low-molecular-weight hep-
arm?
DR. DuBosc: I am not aware of any reports to this effect.
DR. IOANNIs GIATRAS (Renal Fellow, New England Medical
Center): Does heparin administered during hemodialysis decrease
the level of plasma aldosterone?
DR. DuBosE: I am unaware of any measurements in the
literature.
DR. MADIAS: Have you had the opportunity to study the effects
of lithium?
DR. DuBosE: We have studied lithium nephrotoxicity in the rat,
Nephrology Forum: Hyperkalemic hyperchioremic metabolic acidosis 601
but the lithium model was not associated with hyperkalemia.
These animals developed metabolic acidosis as a result of a
"pump" defect.
DR. HARRINGTON: You discussed hypokalemia and the impact
on ammonium secretion in experimental animals that also had
chloride-depletion metabolic alkalosis. What is the effect of
diet-induced hypokalemia on ammonium secretion quantitatively
in the absence of chloride-depletion metabolic alkalosis?
DR. DUBOSE: We have not studied pure hypokalemia, and I am
not aware of any study in humans or in animal models on
ammonium transport in hypokalemia without alkalosis.
DR. ANDREW J. KING (Division of Nephrology, New England
Medical Center): In the treatment of type-TV renal tubular acido-
sis, is there a role for poorly absorbed anions? If you were going
to design an approach that employed poorly absorbed anions,
what would you use?
DR. DUBOSE: What you've proposed seems logical. Since
sulfate is not tolerated well, bicarbonate is reasonable therapy for
a "voltage" lesion. One might need to combine bicarbonate
administration with acetazolamide. Furosemide, rather than
acetazolamide, might work, as it has other beneficial effects,
including an increase in potassium excretion.
DR. MITCHELL S. JACOBSON (Renal Fellow, Division of Nephrol-
ogy, New England Medical Center): Trimethoprim has been de-
scribed as an important cause of hyperkalemia in patients with
AIDS. The dose of trimethoprim in HIV-infected patients is often
much greater than that given for conventional infections. How-
ever, in rare cases hyperkalemia has been described in elderly
patients given conventional doses. In fact, I can recall during my
fellowship a diabetic patient taking oral trimethoprim-sulfa-
methoxazole who developed life-threatening hyperkalemia. Can
you comment on the occurrence of hyperkalemia with conven-
tional doses of trimethoprim? What conditions would predispose
a patient to hyperkalemia in this setting?
DR. DuBosu: The same phenomenon has been reported in
children taking higher doses of trimethoprim in the absence of
significant renal insufficiency. These agents work from the luminal
side, so I assume that it is the drug concentration in the urine that
matters. It's more likely that hyperkalemia would be observed in
prerenal conditions.
DR. HARRINGTON: Could you define disequilibrium pH for the
acid-base neophyte?
DR. DuBosE: Disequilibrium pH is the difference between pH
measured in situ and pH attained when the tubule fluid is
removed and allowed to come to equilibrium. Obviously this
technique applies only to the micropuncture or microperfusion
setting.
Reprint requests to Dr. T D. DuBose, Jr., University of Texas Medical
School-Houston, 6431 Fannin, MSB 4.136, Houston, Texas 77030, USA
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